

51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Trenchant Technologies Capital Corp. (the “**Company**”)
Suite 2380 – 1055 West Hastings Street
Vancouver, BC V6E 2E9

Item 2 Date of Material Change

December 10, 2024

Item 3 News Release

The news release dated December 10, 2024 was disseminated via Market News and Stockwatch on December 10, 2024.

Item 4 Summary of Material Change

The Company announced that its portfolio company, GNQ Insilico (“**GNQ**”), a leading health tech innovator leveraging AI and quantum computing to revolutionize healthcare, appointed Dr. Maliha Hashmi to its board of directors (the “**Board**”).

Item 5 Full Description of Material Change

GNQ appointed Dr. Maliha Hashmi to its Board. This milestone coincides with GNQ’s filing of its first provisional patent for its groundbreaking digital twins platform.

Throughout her illustrious career, Dr. Hashmi has championed the humanization of technology, ensuring that healthcare advancements foster deeper human connections, compassion, and accessibility. Her innovative approach integrates cutting-edge smart systems designed to enhance operational efficiency, elevate patient care, and achieve groundbreaking health outcomes.

Dr. Hashmi has been widely celebrated for her contributions, including recently being ranked #1 among the Top 10 Female Innovators and Leaders Globally by Entrepreneur Mirror. She holds multiple advanced degrees from Harvard University and has served as a World Economic Forum Global Future Expert and V20 Delegate for the G20.

This appointment underscores GNQ’s commitment to driving innovation and excellence, ensuring that technological advancements continue to redefine healthcare for the better.

On December 2, 2024 GNQ filed a provisional patent on insulin dynamics optimization, a method that models relationships between insulin demand, insulin supply and efficiency. This approach uniquely combines quantum-inspired optimization (QIO) with genetic pathway analysis and real-time adaptation, enabling personalized, dynamic treatment optimization that considers multiple biological factors simultaneously.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

None

Item 8 Executive Officer

Eric Boehnke, CEO, 604.307.4274

Item 9 Date of Report

December 12, 2024